ARC-2022 contains lidocaine in a 40 percent concentration in a clear, water-based gel that can be applied directly to painful skin areas of the body. The treatment showed effectiveness in a single-dose phase 1 pharmacokinetic study in adult patients with post-herpetic neuralgia.
Sign up for our FREE Pain E-Weekly for more coverage like this sent to your inbox!
Related Articles on Pain Management:
5 Ways to Safeguard Against Opioid Abuse and Diversion From Robert Saenz, CEO of Tulsa Pain Consultants
Epidural Steroid Injections Increase Blood Glucose Levels in Patients With Diabetes
NeurogesX Appoints Ronald Martell President and Chief Executive Officer
